Introduction: According to the EAU guidelines, botulinum toxin type A (BoNT-A) detrusor injections are one of the last options in the management of overactive bladder before opting for invasive surgery. So far, there have been no studies dedicated exclusively to such patients who have undergone this treatment and in whom this treatment has presumably failed. From the patient’s point of view, there are questions regarding what reasons led to discontinuation, how patients perceive their BoNT-A treatment in hindsight, what further treatment do these patients receive, and how satisfied such patients are with their current situation. Methods: A database of clinical and inpatient records was searched, and 695 records from 406 patients were identified in a 6-year period, who had received BoNT-A detrusor injections. There were 255 cases that were treated with BoNT-A injections into the detrusor muscle where the therapy was not repeated for at least 12 months (= suspected treatment failures). Interviews with these patients were conducted by mail and phone, and 115 questionnaires could be included in the analysis. Results: From the subjective and prospective points of view of the patients, the most common reason for stopping the therapy was a lack of efficacy of BoNT-A injections (39.1%). For 26.1% of all patients, side effects were a reason for dissatisfaction but never a reason for discontinuation. For 10.4%, the reason for stopping the therapy was spontaneous improvement. 35.6% of the respondents had no follow-up therapy. Those with a follow-up therapy mostly returned to anticholinergic treatment (33%). Operations were carried out on 13%, of which about half were highly invasive. For 71.3% of those patients, who were under any current therapy, this therapy led to no improvement or only some improvement of the symptoms. Surprisingly, 50.4% of the respondents would choose to undergo BoNT-A injection therapy again. Discussion/Conclusion: The majority of patients who did not continue BoNT-A therapy are still suffering from lower urinary tract symptoms. The lack of efficacy was the reason for stopping the BoNT-A injection therapy for less than half of the patients. From the patient’s point of view, reasons other than the effectiveness also seem to be relevant in the choice of the treatment. When changing therapy, most returned to drug treatment. However, for the majority of patients with any follow-up therapy, this therapy could not improve the symptoms.

1.
Irwin
DE
,
Milsom
I
,
Hunskaar
S
,
Reilly
K
,
Kopp
Z
,
Herschorn
S
,
.
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study
.
Eur Urol
.
2006
;
50
(
6
):
1306
14
; discussion 14–5.
2.
Coyne
KS
,
Sexton
CC
,
Kopp
ZS
,
Ebel-Bitoun
C
,
Milsom
I
,
Chapple
C
.
The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS
.
BJU Int
.
2011
;
108
(
9
):
1459
71
.
3.
Burkhard
FC
,
Bosch
JLHR
,
Cruz
F
,
Lemack
GE
,
Nambiar
AK
,
Thiruchelvam
N
,
.
EAU guidelines on urinary incontinence
.
2019
. Available from.http://www.uroweb.org/guideline/urinary-incontinence.
4.
Lin
YH
,
Chiang
BJ
,
Liao
CH
.
Mechanism of action of botulinum toxin a in treatment of functional urological disorders
.
Toxins
.
2020
;
12
(
2
):
129
.
5.
Uebersax
JS
,
Wyman
JF
,
Shumaker
SA
,
McClish
DK
,
Fantl
JA
.
Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group
.
Neurourol Urodyn
.
1995
;
14
(
2
):
131
9
.
6.
Gamé
X
,
Khan
S
,
Panicker
JN
,
Kalsi
V
,
Dalton
C
,
Elneil
S
,
.
Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity
.
BJU international
.
2011
;
107
(
11
):
1786
92
.
7.
Del Popolo
G
,
Filocamo
MT
,
Li Marzi
V
,
Macchiarella
A
,
Cecconi
F
,
Lombardi
G
,
.
Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre
.
Eur Urol
.
2008
;
53
(
5
):
1013
9
.
8.
Mohee
A
,
Khan
A
,
Harris
N
,
Eardley
I
.
Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)
.
BJU Int
.
2013
;
111
(
1
):
106
13
.
9.
Dowson
C
,
Watkins
J
,
Khan
MS
,
Dasgupta
P
,
Sahai
A
.
Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates
.
Eur Urol
.
2012
;
61
(
4
):
834
9
.
10.
Veeratterapillay
R
,
Harding
C
,
Teo
L
,
Vasdev
N
,
Abroaf
A
,
Dorkin
TJ
,
.
Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity
.
Int J Urol
.
2014
;
21
(
2
):
175
8
.
11.
Makovey
I
,
Davis
T
,
Guralnick
ML
,
O’Connor
RC
.
Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability
.
Neurourol Urodyn
.
2011
;
30
(
8
):
1538
40
.
You do not currently have access to this content.